Composition and method for treatment of diabetes
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-9301938-B2
Publication Date
2016-04-05
Expiration Date
Abstract
The present invention relates to a method of treating an incretin related disease such as diabetes, obesity and the like by delivery of butyric acid, bile acid, long chain fatty acid or glutamine to the colon by bypassing the upper digestive tract. The composition is combined either by the same or different route of administration with a monoamine reuptake inhibitor such as buproprion.
Core Innovation
The disclosed invention relates to treating incretin-related diseases, including type II diabetes, using oral colon-targeted delivery to administer naturally occurring agents, including glutamine, so that the agents act to stimulate L-cell gut hormone release in the colon. The gut hormones identified include GLP-1, GLP-2, PYY, and oxyntomodulin.
A central aspect of the invention is oral colon-targeted delivery that bypasses release in the stomach and upper gastrointestinal tract. The document also describes a rectal release system as part of the colon-targeted approach, with colon-targeted delivery system formats such as MMX/multimatrix and other colon-targeted release architectures.
The invention combines colon-targeted administration of an incretin-stimulating agent with a monoamine reuptake inhibitor to ameliorate increased compulsive or addictive behaviors associated with the treatment. The document specifically includes bupropion as the monoamine reuptake inhibitor, and reports decreased glucose and lipids and improved satiety or hunger when combined with bupropion.
Claims Coverage
The relevant claims include two independent claims, one directed to a method and one directed to a pharmaceutical composition. The inventive features are centered on oral colon-targeted glutamine that does not release in the stomach or upper gastrointestinal tract, and co-administration of a monoamine reuptake inhibitor to ameliorate an increase in compulsive behavior.
Oral colon-targeted glutamine for treating type II diabetes
Selecting glutamine formulated to release in an oral colon targeted delivery system, and orally administering sufficient formulated glutamine via a colon targeted delivery system to treat type II diabetes.
Monoamine reuptake inhibitor to ameliorate increased compulsive behavior
Orally administering an amount of a monoamine reuptake inhibitor sufficient to ameliorate an increase in compulsive behavior caused by administering the formulated glutamine.
Oral colon-targeted glutamine that does not release in stomach or upper GI
An oral administered glutamine formulated in an oral colon targeted delivery system such that it does not release in either the stomach or upper gastrointestinal tract.
Oral monoamine reuptake inhibitor co-component
Oral administered monoamine reuptake inhibitor as a component of the pharmaceutical composition for the treatment of type II diabetes.
Overall, the independent claims cover colon-targeted oral glutamine for type II diabetes and the inclusion of an oral monoamine reuptake inhibitor to address increased compulsive behavior.
Stated Advantages
Amelioration of an increase in compulsive behavior caused by the glutamine administration.
Decreased glucose and lipids.
Improved satiety or hunger outcomes.
Documented Applications
Treating type II diabetes in an individual using oral colon-targeted glutamine together with an oral monoamine reuptake inhibitor.
A pharmaceutical composition for the treatment of type II diabetes comprising orally administered glutamine in an oral colon targeted delivery system that does not release in the stomach or upper gastrointestinal tract, together with an orally administered monoamine reuptake inhibitor.
Interested in licensing this patent?